Vicky Hahne serves as the Chief Financial Officer at Celcuity Inc., a clinical-stage biotechnology company focused on developing targeted therapies for various cancers. With a robust background in finance and a keen understanding of the biotechnology sector, Hahne has been instrumental in guiding Celcuity through its growth phases. Prior to joining Celcuity, she held significant roles in financial management and strategic planning, working with various companies in the life sciences industry. Her expertise in navigating complex financial landscapes has been vital in securing the funding necessary for Celcuity's research and development efforts. In her role as CFO, Vicky Hahne is responsible for overseeing all financial aspects of the company, including budgeting, financial planning, and investor relations. Her strategic vision has helped Celcuity maintain a strong financial position, enabling the company to advance its lead therapeutic candidate, gedatolisib, through clinical trials. Hahne's leadership has been pivotal in establishing partnerships and collaborations that have bolstered Celcuity's research capabilities. Under her guidance, the company has successfully managed its resources to support ongoing and future clinical programs, positioning Celcuity as a promising player in the oncology field. Vicky Hahne's achievements extend beyond her role at Celcuity. She is recognized in the industry for her contributions to financial strategy and corporate governance within biotechnology. Her ability to communicate complex financial information to stakeholders has made her a trusted figure in the investment community. Hahne's dedication to advancing cancer treatment through sound financial management continues to drive Celcuity's mission to bring innovative therapies to patients in need.